Pathologist, Department of Pathology, Doce de Octubre University Hospital Madrid
BIOGRAPHY
APR 07, 2022 3:00 PM CEST
RET aberrations and EGFR exon 20 insertions testing in the complex NSCLC biomarker landscape
Presented at:
OncomineWorld 2022: A Virtual NGS Education Meeting
Speaker
Abstract
In this presentation the speaker will discuss latest developments in NSCLC precision therapy and biomarker landscape, and importance of NGS in NSCLC biomarker testing.
He will review the NSCLC biomarkers and targeted treatment landscape and current the guidelines for NSCLC biomarker testing. A special focus will be on RET fusions and EGFR exon 20 insertions as some of the latest biomarkers becoming subject to routine testing. In light of all the discussed he will argue it is time to implement NGS as front-line biomarker testing technology in NSCLC.
You May Also Like
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
Loading Comments...